Compare TORO & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TORO | ENTX |
|---|---|---|
| Founded | 2022 | 2010 |
| Country | Cyprus | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.5M | 147.4M |
| IPO Year | 2022 | 2015 |
| Metric | TORO | ENTX |
|---|---|---|
| Price | $6.06 | $2.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 25.0K | ★ 344.3K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | ★ 36.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.95 | $0.91 |
| 52 Week High | $8.50 | $4.20 |
| Indicator | TORO | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 49.61 |
| Support Level | $4.87 | $2.73 |
| Resistance Level | $6.15 | $3.10 |
| Average True Range (ATR) | 0.27 | 0.18 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 20.03 | 45.74 |
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.